We don’t support this browser anymore.
This means our website may not look and work as you would expect. Read more about browsers and how to update them here.

Skip to main content
  • Register
  • Help
  • Contact us

Nordic Nanovector ASA (NANOV) NOK0.2

Sell:11.50 NOK Buy:11.52 NOK Change: 0.36 NOK (3.23%)
Prices delayed by at least 15 minutes | Switch to live prices |
Sell:11.50 NOK
Buy:11.52 NOK
Change: 0.36 NOK (3.23%)
Prices delayed by at least 15 minutes | Switch to live prices |
Sell:11.50 NOK
Buy:11.52 NOK
Change: 0.36 NOK (3.23%)
Prices delayed by at least 15 minutes | Switch to live prices |
The selling price currently displayed is higher than the buying price. This can occur temporarily for a variety of reasons; shortly before the market opens, after the market closes or because of extraordinary price volatility during the trading day.

Business summary

Nordic Nanovector ASA is a Norway-based company active in the biotechnology industry. It is engaged in the development and commercialization of targeted therapeutics for hematological cancers. Its main product candidate is Betalutin, comprising a tumor-seeking anti-CD37 antibody conjugated to a low intensity radionuclide (Lutetium 177). It is designed improve treatment of Non-Hodgkin Lymphoma (NHL) and advanced through clinical development. Additionally, the Company is engaged in the development of its Antibody-Radionuclide-Conjugate (ARC) portfolio to treat various selected cancer indications. It has two subsidiaries, Nordic Nanovector GmbH and Nordic Nanovector Ltd.

Contact details

Kjelsasveien 168 B
+47 (2) 2183301

Important dates

Future events
There are no future events available.
Past events
There are no past events available.

General stock information

Short code:
Market cap:
1.33 billion NOK
Shares in issue:
98.08 million
Oslo Stock Exchange
Norwegian Krone
Oslo All Share Index

Key personnel

  • Erik Skullerud
    Chief Executive Officer
  • Malene Brondberg
    Chief Financial Officer
  • Sandra Jonsson
    Chief Operating Officer
  • Lars Nieba
    Chief Technology Officer
  • Jostein Dahle
    Chief Scientific Officer
  • Gabriele Elbl
    Vice President - Global Regulatory Affairs
  • Rosemarie Corrigan
    Chief Quality Officer
  • Pierre Dodion
    Chief Medical Officer

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Business summary, contact details and key personnel provided by Thomson Reuters. Important dates provided by Digital Look Ltd. General stock information provided by Reuters.


The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.

Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.